Why GLP-1 Medications Are Inaccessible to Most Americans — And What’s Being Done About It

The Paradox: Drugs That Work, a Population That Can’t Access Them

It is genuinely difficult to overstate what GLP-1 receptor agonists represent in the history of metabolic medicine. For decades, the treatment of obesity was characterized by modest results, high relapse rates, and a clinical pessimism born of repeated disappointments. Behavior modification, diet programs, and earlier pharmacological interventions produced single-digit percentage weight loss in most patients, with most of those gains lost within a year or two of stopping treatment.

Semaglutide and tirzepatide changed that picture substantially. The STEP clinical trials for semaglutide (Wegovy) demonstrated average body weight reductions of 15–22% over 68 weeks — results that had previously required bariatric surgery. The SURMOUNT trials for tirzepatide (Zepbound) showed reductions up to 22.5% in the highest-dose arm, with some participants losing more than a third of their body weight. The SELECT trial, published in 2023, demonstrated that semaglutide reduced cardiovascular mortality in people with obesity and established cardiovascular disease — moving the clinical argument from cosmetic to life-extending.

The population that could benefit from these medications is not a niche. Roughly 100 million Americans meet clinical criteria for obesity (BMI ≥ 30). Hundreds of millions more live with metabolic syndrome, prediabetes, or type 2 diabetes — conditions for which GLP-1 receptor agonists have demonstrated meaningful clinical benefit. These are not edge cases. These are the central metabolic disease burden of the American population.

→ Related: GLP-1 Benefits Beyond Weight Loss: Heart, Kidney, Brain & More — the SELECT cardiovascular trial, FLOW kidney trial, EVOKE Alzheimer’s data, addiction signals, and testosterone findings. The breadth of benefit makes the access failure more consequential.

And yet the vast majority of these people cannot access the drugs.

This piece does not aim to be a polemic. The story of why GLP-1 medications are inaccessible to most Americans involves multiple actors — pharmaceutical manufacturers, insurers, employers, policymakers, regulators, and the courts — each operating under their own incentive structures and legal constraints. Understanding what happened, and what is actually being done about it, requires engaging with that complexity honestly. The evidence suggests the situation is a structural failure. That observation doesn’t require assigning blame to be useful.

I write this as a California attorney with no affiliation to any pharmaceutical company, insurer, pharmacy, or peptide supplier. I write it because the landscape of information around GLP-1 access is dominated by people who are selling something — either the drugs themselves, or the narrative that the drugs are dangerous, or the narrative that any option is fine. An independent voice seems worth having.

The Price Problem

The list prices for GLP-1 medications in the United States are striking by any international comparison. As of mid-2026, without insurance coverage:

Note: International prices are approximate, converted from local currency, and vary by pharmacy, country, and plan. They are cited for comparative context only, not as actionable purchasing guidance.

The Manufacturers’ Justification

Novo Nordisk and Eli Lilly, the manufacturers of semaglutide and tirzepatide respectively, have articulated the standard pharmaceutical industry position: high US prices reflect the cost of drug development, clinical trials, and the risk capital invested in compounds that might not succeed. The argument has real substance. GLP-1 drug development required decades of scientific work, enormous clinical trial infrastructure, and genuine financial risk at each stage. Not every compound that enters development reaches approval.

The counterarguments, however, are also substantial.

The most visible evidence of the pricing problem, however, is not the NIH funding question — it is the international price differential. The same molecule, manufactured in the same facilities, with the same clinical data, sells for 10 to 15 times more in the United States than in comparable wealthy countries. The difference is not explained by development cost recovery — it is explained by negotiating leverage. European governments negotiate drug prices centrally and can credibly threaten market exclusion. The US government, until the Inflation Reduction Act created a limited Medicare negotiation framework, had no equivalent mechanism.

The Savings Card Problem

Both Novo Nordisk and Eli Lilly offer manufacturer savings card programs that can reduce the out-of-pocket cost for eligible commercially insured patients to as little as $25–$35 per month. These programs are not trivial — for patients who have commercial insurance that covers the drug but faces high cost-sharing, savings cards can make treatment accessible.

But the programs have a critical structural limitation: they are not available to patients enrolled in Medicare or Medicaid. Federal anti-kickback laws prohibit manufacturers from providing savings cards to government program beneficiaries. The practical result is that the savings programs designed to address the affordability problem reach the patients least likely to be in financial need, while leaving out the patients — elderly Medicare enrollees and low-income Medicaid beneficiaries — who carry the highest obesity burden and the least ability to pay.

The Insurance Gap

Even for Americans who have health insurance, access to GLP-1 medications for weight management has been systematically limited by how insurers classify the drugs — and the economic logic that drives those classifications.

The Lifestyle Drug Problem

Many commercial health plans and employer-sponsored plans categorize GLP-1 medications prescribed for weight management as “lifestyle drugs” or “cosmetic medications” — a classification that allows them to be excluded from coverage entirely, or subject to extraordinary prior authorization hurdles. This classification persists even for patients with obesity-related comorbidities: hypertension, type 2 diabetes, obstructive sleep apnea, or established cardiovascular disease. These are not cosmetic problems. They are the leading causes of mortality and morbidity in the American population.

The Employer Math Problem

For the large share of Americans covered by employer-sponsored insurance, the coverage question is not primarily a clinical one — it is a financial modeling question. GLP-1 medications cost approximately $15,000 per year at list price. The downstream savings from reduced cardiovascular events, fewer diabetes complications, lower hospitalization rates, and reduced disability are real, but they materialize over a period of years to decades.

The employer math works against coverage when the average employee tenure is 3–5 years. If an employer pays for three years of GLP-1 therapy and the employee leaves or changes plans at year four, the employer has borne the full cost and captured none of the long-term savings — which accrue to the next insurer, or to Medicare when the patient eventually enrolls. This is a classic externality problem: the cost and the benefit fall on different parties at different times. There is no obvious market mechanism that corrects for it.

The Medicare Gap

Medicare Part D was, for many years, legally prohibited from covering drugs approved primarily for weight loss. This prohibition was rooted in a 1999 policy determination and was codified into how Part D formularies were structured. The practical effect: Medicare beneficiaries — a population with high obesity prevalence and high cardiovascular risk — could access GLP-1 medications only when prescribed for type 2 diabetes, not for obesity.

The Treat and Reduce Obesity Act (TROA), first introduced in Congress in 2012, has been reintroduced in multiple sessions with bipartisan support. Its central provision would require Medicare to cover anti-obesity medications, including GLP-1 receptor agonists. As of mid-2026, full Medicare coverage for weight management indications has not been enacted into law, though there have been regulatory changes that modestly expanded coverage for beneficiaries with cardiovascular disease. Patients who are uncertain about their current Medicare coverage status should verify with their plan directly.

The Appeal Process That Most Patients Never Use

Insurance coverage denials are not final. Federal law requires insurers to provide an internal appeal process, and most states require an external independent review option as well. In theory, a patient with a documented medical necessity case — strong clinical documentation, comorbidity evidence, prior treatment attempts — has a legitimate path to coverage even after an initial denial.

In practice, the appeal process is opaque, burdensome, and designed in ways that assume an organized, persistent advocate. Most patients — particularly those who are elderly, have limited English proficiency, lack administrative support, or are managing significant illness — do not successfully navigate it. The structural effect is that coverage is functionally determined less by medical criteria than by who has the time and knowledge to fight for it.

The Compounding Window — and What Happened to It

One of the more instructive chapters in the GLP-1 access story is the compounding window that opened during the drug shortage period and the regulatory and legal battle that followed when FDA moved to close it.

The Legal Basis for Compounding During a Shortage

Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may compound copies of FDA-approved drugs under certain conditions — one of the most significant being that the branded drug is on FDA’s Drug Shortage List. When semaglutide and, later, tirzepatide appeared on the shortage list (reflecting genuine supply constraints that began in 2022 and persisted through 2024 and into 2025), compounding pharmacies had a legal basis to produce these compounds and dispensing physicians and telehealth platforms could prescribe compounded versions legally.

The practical effect was significant. Compounded semaglutide was available through licensed compounding pharmacies and telehealth-connected prescribers at roughly one-quarter to one-third of the brand-name price — putting medically supervised GLP-1 therapy within reach for a population that had no other legitimate access path.

The FDA Removes the Shortage Designation

In 2025, the FDA began the process of removing semaglutide from the drug shortage list, reflecting Novo Nordisk’s representation that supply had caught up with demand for the branded products. The legal effect of this removal was to eliminate the shortage-based legal basis for most compounding of semaglutide.

This produced immediate practical harm for patients. Millions of people who had found a legitimate, physician-supervised, affordable access path suddenly found that path legally uncertain. Telehealth platforms that had built businesses around compounded semaglutide programs faced abrupt regulatory exposure. The transition period was — to put it charitably — not designed with patient continuity of care as a primary consideration.

The Legal Challenges and the Shifting Landscape

The compounding pharmacy and telehealth industry did not accept the shortage removal quietly. Multiple legal challenges were filed by compounding pharmacy associations and telehealth platforms, arguing procedural deficiencies in how FDA conducted its shortage determination. The litigation produced a genuinely unsettled landscape in 2025 and into early 2026 — with courts at different points staying FDA’s enforcement, lifting those stays, and remanding determinations back to the agency. By June 2026, the FDA had declared both semaglutide and tirzepatide shortages fully resolved, ending the legal basis for mass-market compounding and rendering the access pathway that served millions of patients largely unavailable. The compounding window is now closed for most patients.

The Base vs. Salt Issue

A technical but legally significant aspect of the compounding dispute involves the specific chemical form of the compound. Branded Ozempic and Wegovy use semaglutide in its free base form. Many compounding pharmacies were working with semaglutide sodium (the salt form), which is commercially available through pharmaceutical ingredient suppliers at lower cost. FDA took the position that the shortage exemption required compounders to use the same compound as the branded product — the free base, not the sodium salt form. This position added another layer of restriction on top of the shortage removal, affecting compounders who had sourced the salt form.

The technical difference matters because it affects what compound was actually being dispensed to patients, and raises questions about whether the clinical equivalence assumptions in prescribing were fully grounded. The legal difference matters because it affects which compounders fall within or outside the permissible exception.

The Gray Market That Filled the Gap

As access to brand-name GLP-1 medications remained out of reach for most Americans on cost grounds, and as the compounded access pathway became legally uncertain, a third channel grew to absorb demand: the research peptide market.

What Research Peptides Are (and Aren’t)

Research peptides are chemical compounds — including GLP-1 receptor agonists — sold legally for in vitro laboratory research purposes. They are not FDA-approved for human use. They are not manufactured under pharmaceutical Good Manufacturing Practices (GMP). They are not dispensed by licensed pharmacists or supplied under a prescriber’s oversight. Their sale is not prohibited by federal law in the same way that prescription drug distribution without a license is — but their use by humans for therapeutic purposes occupies a genuine gray zone.

The research peptide market has existed for decades, primarily serving legitimate academic and pharmaceutical research applications. In that context, the not-for-human-use designation is a straightforward regulatory constraint: researchers reconstituting peptides for cell culture experiments are not treating patients.

What changed in the 2022–2026 period is that the GLP-1 access crisis created a new category of demand: people who had tried the legitimate channel, found it unavailable or unaffordable, and turned to the research peptide market as the only remaining option at a price they could afford.

Who Uses This Market

It is worth being precise about who populates this market, because the public discourse often defaults to two inaccurate characterizations: naive consumers being preyed upon by unscrupulous vendors, or health-conscious biohackers voluntarily accepting risks for performance optimization. The reality is more complicated and more sympathetic.

The Risks Are Real

The quality and safety risks in the research peptide market are meaningfully different from those in pharmaceutical or licensed compounding supply chains. Manufacturing outside GMP standards means variable quality control, inconsistent purity, potential for microbial contamination, and reduced confidence in dosing accuracy. Endotoxin contamination — a risk specific to injectable products manufactured without pharmaceutical-grade sterility controls — can produce fever, chills, and systemic immune responses that are unpleasant and occasionally dangerous.

There is no surveillance system that tracks adverse events from research peptide use, which means the frequency of harm is genuinely unknown. What we can say is that the theoretical risk pathways are well-understood, that some categories of harm (endotoxin reactions, identity failures) have been documented through community testing campaigns, and that the risks are not uniformly distributed — a buyer who independently verifies product quality through third-party testing is in a materially different position than one who does not.

If you are considering research peptide products, the information in our Peptide Quality Risks Guide and Peptide Supplier Evaluation Guide is intended to help you understand and reduce those risks with eyes open. We don’t sell anything, and we don’t have a financial interest in whether you use these products or not.

The Influencer Problem

The GLP-1 access crisis has produced, predictably, a large and aggressively monetized information ecosystem. Understanding it is worth some attention — because the way information flows in this space has real consequences for patient safety.

The Ecosystem

On one end of the spectrum are the pharmaceutical company-funded patient advocacy organizations and "educational" resources that emphasize the need for brand-name products and the dangers of compounded or research alternatives. On the other end are the social media influencers who promote specific peptide suppliers, unconventional dosing protocols, and combination regimens with little to no acknowledgment of risks, disclosure of affiliate compensation, or medical training.

In between are a range of actors: telehealth platforms with economic interests in expanding their patient base; compounding pharmacies with economic interests in defending the compounding pathway; functional medicine practitioners with genuinely varied quality of clinical judgment; and a large category of self-described “wellness educators” whose primary compensation model is affiliate commissions on product sales.

The Specific Harm

The influencer layer of this ecosystem causes a specific, identifiable harm. It is not simply misinformation in the abstract. It is misinformation delivered to a population that:

• Is already underserved by the medical system, and therefore particularly dependent on informal information channels;
• Has genuine metabolic health needs that create emotional investment in finding solutions;
• Often lacks the background to evaluate the quality of the information being offered; and
• Is being pushed toward purchasing decisions that benefit the information provider financially.

The combination of those factors — vulnerability, genuine need, information asymmetry, and conflicted financial incentives — creates conditions where bad information does more than the usual amount of damage.

The question worth asking of any GLP-1 information source is simple: does this source benefit financially from the conclusions it reaches? If the answer is yes, the conclusions deserve more scrutiny, not less.

What’s Actually Being Done

The GLP-1 access crisis is not being ignored at the policy level. There are several genuine efforts underway to address different aspects of the problem — with varying levels of momentum, and widely varying timelines to impact. An honest assessment requires acknowledging both what is real and what is slow.

Congressional Action: The Treat and Reduce Obesity Act

The Treat and Reduce Obesity Act has been introduced in multiple Congresses with bipartisan support. Its core provision would require Medicare to cover FDA-approved anti-obesity medications, including GLP-1 receptor agonists, for the weight management indication. As of mid-2026, full TROA passage has not occurred, though partial measures have been implemented through regulatory action at CMS that extend some GLP-1 coverage to Medicare beneficiaries with established cardiovascular disease.

The trajectory of TROA passage is complicated by the same math that affects employer coverage decisions: the Congressional Budget Office scores the cost of covering anti-obesity medications over a 10-year budget window without full credit for the downstream savings that would reduce Medicare’s own long-term costs. That scoring methodology is contested by health economists who argue it systematically undervalues preventive pharmacotherapy, but it has real political consequences for passage.

IRA Drug Price Negotiation

The Inflation Reduction Act created a framework for Medicare to negotiate drug prices directly with manufacturers — a significant structural change after decades of statutory prohibition on such negotiation. The first round of negotiations covered 10 drugs (none of them GLP-1 medications) with negotiated prices taking effect in 2026. GLP-1 receptor agonists, because they are relatively recently approved, are not immediately eligible for negotiation under the IRA’s timeline rules — small-molecule drugs qualify for negotiation after 9 years post-approval, biologics after 13. Semaglutide (approved in 2017 for diabetes) becomes eligible in the next negotiation cycle, though whether it will be selected is a separate question.

The Biosimilar and Generic Pathway

Semaglutide’s patent landscape is complex, with multiple overlapping patents on the compound, formulation, device, and method-of-treatment. The earliest relevant patents on the semaglutide molecule are approaching expiration within the next few years, potentially opening a pathway for generic or biosimilar entry. However, GLP-1 receptor agonists present manufacturing challenges that make rapid generic entry unlikely — biosimilar manufacturing of peptides and biologics is technically demanding, and regulatory requirements for demonstrating biosimilarity add time and cost to market entry.

The realistic timeline for meaningful generic or biosimilar competition that would materially lower prices is likely measured in years to decades, not months. Several companies have announced biosimilar programs; actual approval and market availability is a different story.

→ Related: Health Canada's Generic Semaglutide Approval: Cross-Border Cost Comparison and US Importation Law — Canada's generic approval is an early signal of what the post-patent landscape may look like, and illustrates the US-international price gap in concrete terms.

International Pricing Pressure

Public and political pressure around the US-international price differential for GLP-1 medications has grown substantially. Congressional hearings have featured direct questioning of Novo Nordisk and Eli Lilly executives about international pricing. The political pressure does not have a direct legal mechanism that forces price reduction, but it has contributed to both companies expanding their patient assistance programs and announcing various pricing commitments for lower-income populations.

Manufacturer Patient Assistance Programs

Both Novo Nordisk and Eli Lilly maintain patient assistance programs (PAPs) that provide free or reduced-cost medication to qualifying uninsured or underinsured patients. The income eligibility thresholds and documentation requirements vary and are subject to change; patients should apply directly through the manufacturer programs rather than relying on secondhand information about current terms.

The honest assessment of PAPs is that they serve a real need for the qualifying population, but they do not scale to address the full access gap. They require administrative effort to apply, have income and insurance eligibility restrictions, and create no sustainable pricing structure — they are a charity layer on top of an unaffordable price, not a solution to the underlying pricing problem.

State-Level Medicaid Expansion

Some states have taken independent action to expand Medicaid coverage for anti-obesity medications. California, Colorado, and several other states have moved to include GLP-1 medications in their Medicaid formularies for weight management indications, ahead of any federal requirement to do so. This represents meaningful progress for low-income patients in those states, but coverage varies widely across the country and is subject to ongoing budget pressures.

What Patients Can Do Right Now

The structural analysis above describes a system that has failed a large population. That analysis does not help the individual patient who needs access today. Here is an honest rundown of the options that actually exist, with their tradeoffs.

If You Have Insurance That Has Denied Coverage

• → Request a written denial letter stating the specific reason. You cannot appeal effectively without knowing the stated basis for denial. Insurers are required to provide this.
• → Have your prescribing physician write a medical necessity letter that directly addresses the stated reason for denial, documenting your clinical history, comorbidities, and prior treatment attempts. This is the most important single step in a successful appeal.
• → Submit the internal appeal with supporting documentation. Most plans have 30–60 day timelines for responding to internal appeals. If denied again, request an external independent review — insurers in most states are legally required to offer this.
• → Our insurance appeal letter templates walk through the full process with sample language your prescriber can adapt.

Manufacturer Savings and Assistance Programs

• → Novo Nordisk savings cards (for Ozempic and Wegovy) can reduce commercially insured patients’ cost to $25–$35/month. Apply at NovoCare.com. Not available for Medicare/Medicaid enrollees.
• → Eli Lilly savings programs (for Mounjaro and Zepbound) have similar structures for commercially insured patients. Apply through LillyDirect or the Lilly Cares Foundation for uninsured patients with financial need.
• → Our Patient Assistance Program Screener helps identify which programs you may qualify for based on your insurance status and income.

HSA and FSA Eligibility

• → GLP-1 medications prescribed by a physician for a qualifying medical condition are generally eligible for HSA/FSA reimbursement as medical expenses. At $900–$1,400/month, pre-tax purchasing through an HSA or FSA can reduce effective cost by 20–35% depending on your tax bracket.
• → See our GLP-1 HSA/FSA Guide for a full breakdown of eligibility rules, contribution limits, and how to document expenses for reimbursement.

Compounded GLP-1 Programs

• → For patients who qualify medically and whose prescribers can document clinical need, physician-supervised compounded GLP-1 programs through licensed pharmacies remain available in some forms, though the legal landscape is evolving. Programs range from $150–$400/month depending on compound, dose, and platform.
• → Verify current legal status with your prescriber and the compounding pharmacy before enrolling. See our compounding guide and pharmacy comparison guide for current information.

If You Are Considering Research Peptide Options

• → We are not in a position to recommend or endorse research peptide products for human use. We recognize the reality that people are using them, and we think honest, independent information about the risks and how to reduce them is more valuable than pretending the market doesn’t exist.
• → The most important risk reduction steps are: independent third-party testing for identity and purity (including endotoxin testing), prescriber supervision if at all possible, and understanding the specific risk profile of what you are doing. Our Peptide Supplier Guide and Peptide Quality Risks Guide cover this in detail.
• → The peptide testing labs guide and how to read a Certificate of Analysis are practical starting points for anyone trying to evaluate product quality independently.

Frequently Asked Questions